For this aim, we evaluated the MET copy number (CN) status in cfDNA and the MET expression in CTCs from a cohort of cancer patients with different tumor types and evaluated its clinical potential to detect the appearance of resistances and to guide the treatment with anti-MET drugs in a noninvasive manner. The gene discussed is MET; the disease is cancer.